Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies

CAMBRIDGE, Mass. and SUZHOU, China, Jan. 7, 2021 -- (Healthcare Sales & Marketing Network) -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announ... Biopharmaceuticals, Venture Capital Kira Pharmaceuticals
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news